Watch out for government to take a “back door” approach to stealth drug price controls. Such was the topic recently discussed at a Morgan Stanley dinner and put in report form, which was reviewed by ValueWalk. Political rancor regarding a single payer system or overt price controls are likely to be a smokescreen to pressure the back door solution, those attending the March 23 dinner were told. Plus there is the “threat” of a little known payment committee, the “death panel,” that could come into play. The report comes as Evercore ISI recently predicted that drug price controls are unlikely….
Investors Warned At Morgan Stanley Dinner About Stealth Drug Price Controls
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.